Blocking SIRPα on neutrophils with anti-SIRPα antibodies significantly enhances ADCC mediated by IgA2 variants of cetuximab and trastuzumab against HER2-positive breast cancer cells and EGFR-positive epidermoid carcinoma cells (46). Here, SIRPA is linked to breast carcinoma.